Schizophrenia Tied to Higher Risk for Severe COVID-19
Risk higher despite lower infection risk and regardless of sociodemographic and medical factors
mRNA-1273 Continues to Be Efficacious at Five Months
Vaccine efficacy was 93.2 percent for preventing COVID-19 illness, 98.2 percent for preventing severe COVID-19
Highest Parental COVID-19 Vaccine Hesitancy Seen Among Most Impacted
Black parents and those of publicly insured children show greatest vaccine hesitancy
Live Attenuated Zoster Vaccine Safe for Patients Receiving TNF Inhibitors
No cases of varicella infection found; cumulative incidence of varicella infection or shingles was 0 percent
Vaccines Effective in Preventing Symptomatic COVID-19 in Health Care Workers
Findings seen even for those at risk for severe disease and racial and ethnic groups disproportionately affected by the pandemic
Pfizer to Ask FDA Soon for Approval of Its COVID-19 Vaccine for Younger Children
Right now, COVID-19 vaccines are only approved for children 12 years and older
From 1999 to 2019, Death Rates Higher in Rural Versus Urban Areas
Death rates higher in rural areas for both males and females; difference in rates widened during study period
Overall Cancer Incidence, Mortality Lower for U.S. Hispanics
But rates higher for infection-related cancers, such as liver and stomach cancers, and cervical cancer
Antibodies ID’d in Neonates of Women Vaccinated Against COVID-19
All 36 neonates had high levels of anti-S IgG; in 34 of 36 neonates, levels exceeded 250 U/mL
WHO Issues Guidance for Use of Casirivimab-Imdevimab in COVID-19
Combo conditionally recommended for patients with nonsevere disease at risk for severe disease, seronegative patients with severe infection
